52,95 €
52,95 €
inkl. MwSt.
Sofort per Download lieferbar
payback
26 °P sammeln
52,95 €
52,95 €
inkl. MwSt.
Sofort per Download lieferbar

Alle Infos zum eBook verschenken
payback
26 °P sammeln
Als Download kaufen
52,95 €
inkl. MwSt.
Sofort per Download lieferbar
payback
26 °P sammeln
Jetzt verschenken
52,95 €
inkl. MwSt.
Sofort per Download lieferbar

Alle Infos zum eBook verschenken
payback
26 °P sammeln
  • Format: PDF

Intended to be a single source of information, this book covers a wide range of topics on the changing landscape of drug R&D, emerging applications of big data, AI and machine learning in drug development, and the build of robust data science organizations to drive biopharmaceutical digital transformations.

Produktbeschreibung
Intended to be a single source of information, this book covers a wide range of topics on the changing landscape of drug R&D, emerging applications of big data, AI and machine learning in drug development, and the build of robust data science organizations to drive biopharmaceutical digital transformations.


Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Autorenporträt
Harry Yang, Ph.D., is the Vice President and Head of Biometrics at Fate Therapeutics. He has 27 years of experience across all aspects of drug R & D, from early target discovery, through pre-clinical, clinical, translational science, and CMC programs to regulatory approval and post-approval lifecycle management. He played a pivotal role in the successful submissions of 5 biologics license appllications (BLAs) that ultimately led to marketing approvals of five biological products. He has published 8 statistical and data science books, 28 book chapters, over 100 peer-reviewed articles, and 3 industry white papers on diverse scientific, statistical, and data science subjects. He is a frequent invited speaker at national and international conferences. He has also developed statistical courses and conducted trainings at the United States Food and Drug Administration (FDA) and United States Pharmacopeia (USP).
Rezensionen
"The book offers a beautiful journey to explore the application of AI and ML in DrugDevelopment. Even though it cannot replace academic courses in AI, ML andhealthcare,authors provide very important and interesting updates regarding the evolution andadvances achieved in this field the past 10 years."

Ramzi El Feghali, ISCB News, May 2024.